Preventive effects of Eicosapentaenoic acid (EPA) on stroke recurrence and a symptom state in chronic stroke patients with dyslipidemia.

Preventive effects of Eicosapentaenoic acid (EPA) on stroke recurrence and a symptom state in chronic stroke patients with dyslipidemia. - Preventive effects of Eicosapentaenoic acid (EPA) on stroke recurrence and a symptom state in chronic stroke patients with dyslipidemia.

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000006416

Enrollment

100

Registered

2011-09-30

Start date

2009-01-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic stroke patients with dyslipidemia

Interventions

pretreatment(Aspirin100mg/day) Eicosapentaenoic Acid ethyl ester 1800mg/day is added on pretreatment(Aspirin100mg/day)

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Chronic stroke patients with dyslipidemia fulfilled following conditions at baseline will be enrolled (targeted) 1. Stroke (Chronic athero thrombotic brain infarction, lacunar infarction or asymptomatic cerebral infarction identified by CT or MRI) onset over 6 months prior to study enrollment 2.Hyperlipidemia(especially high TG/low HDL-C) patients with well-defined 3.Written informed consent for this study is obtained

Exclusion criteria

Exclusion criteria: Following patients will be excluded from this study 1.SBP>=180mmHg or DBP>=110 2.Patirnts who are bleeding (Hemophilia, intracranial bleeding, Gastrointestinal bleeding, Urinary tract bleeding, Hemophysis, Vitreous hemorrhage) 3.Patients with known bleeding disorders or a predisposing condition 4.Severe liver or renal dysfunction 5.Malignancy 6.Scheduling the operation 7.Past history of severe adverse effect by Aspirin or Eicosapentaenoic Acid ethyl ester 8.Patients who are inadequate by physician's decision

Design outcomes

Primary

Measure	Time frame
Endothelial function(FMD:Flow Mediated Dilation)	—

Secondary

Measure	Time frame
1.IMT(intima Media Thickness) 2.Endothelial function(ADMA:Asymmetric Dimethyl Arginine) 3.Inflammatory markers(hs-CRP:High sensitivity C-reactive protein) 4.Adiponectin 5.Serum lipid(TC,HDL-C,TG) 6.Plasma fatty acid(EPA/AA ratios)	—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026